Novartis AG (NVS)
| Market Cap | 304.21B +22.5% |
| Revenue (ttm) | 56.69B +2.7% |
| Net Income | 12.76B -6.6% |
| EPS | 6.61 -3.4% |
| Shares Out | 1.90B |
| PE Ratio | 23.85 |
| Forward PE | 17.34 |
| Dividend | $3.08 (1.93%) |
| Ex-Dividend Date | Mar 11, 2026 |
| Volume | 1,294,325 |
| Open | 159.90 |
| Previous Close | 163.09 |
| Day's Range | 159.63 - 160.93 |
| 52-Week Range | 121.57 - 170.46 |
| Beta | 0.49 |
| Analysts | Hold |
| Price Target | 157.83 (-1.78%) |
| Earnings Date | Jul 21, 2026 |
About NVS
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for NVS stock is "Hold." The 12-month stock price target is $157.83, which is a decrease of -1.78% from the latest price.
News
A Novartis Heart Drug Trial Stumbles. Can a Rare-Disease Treatment Lift Shares?
In a consequential week for Novartis, the Swiss drug maker released results for two of three trials that Wall Street has watched for in the second half of the year.
Novartis' Pelacarsen Fails To Meet Primary Endpoint In Phase III Lp(a)HORIZON Trial
(RTTNews) - Novartis AG (NVS), a pharmaceutical company, on Friday announced that its phase III Lp(a)HORIZON trial of pelacarsen, an investigational cardiovascular therapy, failed to meet the primary ...
A highly anticipated cholesterol drug from Novartis failed to reduce the risk of severe cardiovascular outcomes in a Phase 3 study
The Phase 3 study found a drug didn't reduce the risk of cardiovascular events like heart attacks and strokes.
Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint
The company's shares declined in after-hours trading after the drug failed to reduce the risk of cardiovascular events in a Phase 3 study.
Novartis, Ionis Tumble On Surprise Flop For Heart Drug
Novartis said late Friday its Ionis-partnered Lp(a) blocker failed in testing. The results sent Novartis and Ionis stocks tumbling.
Ionis, Novartis' key experimental heart drug fails in late-stage trial
Ionis Pharmaceuticals and partner Novartis' experimental drug to lower high levels of a cholesterol-carrying particle in heart patients failed in a late-stage trial, the companies said on Friday.
Novartis announces Phase 3 pelacarsen study did not meet primary endpoint
Ionis Pharmaceuticals (IONS) partner Novartis (NVS) announced that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes trial, did not meet its primary endpoint of reducing ...
Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals
(RTTNews) - This week's biotech roundup saw a flurry of FDA and EU approvals across neurology, oncology, cardiology, and rare diseases, alongside new partnerships, trial readouts, and restructuring mo...
Drugmakers quietly halted autoimmune drug trials because of deaths or problematic side effects, raising questions about disclosure around experimental research
Trial freezes by Novartis and Bristol Myers have triggered a race to understand why a promising autoimmune treatment turned risky.
Novartis Rises as $3.22 Billion Deal Targets Faster Drug Delivery
Novartis Rises as $3.22 Billion Deal Targets Faster Drug Delivery
Novartis Signs Up To $3.2B Hybrozyme Deal With Alteogen
(RTTNews) - Alteogen Inc. (196170.KQ), a South Korea-based biopharmaceutical company specializing in platform technologies, announced it has entered into an option and license agreement with Novartis ...
Novartis could cut about 130 jobs in Basel site relocation
Novartis could cut about 130 jobs in Switzerland as it relocates laboratory activities and shuts down some production in Basel, the Swiss drugmaker said on Wednesday.
Novartis signs deal worth up to $3.2 billion for Alteogen's drug delivery technology
South Korea's Alteogen said on Wednesday it has signed a deal with Novartis worth up to $3.22 billion, giving the Swiss drugmaker access to its technology to make injectable versions of intravenous dr...
A Look at Novartis AG (NVS) After 6.0% Gain -- GF Value $130.84 vs Price $161.25
A Look at Novartis AG (NVS) After 6.0% Gain -- GF Value $130.84 vs Price $161.25
Novartis Jumps 6% as MS Drug Meets Goals in Two Phase 3 Trials
Novartis Jumps 6% as MS Drug Meets Goals in Two Phase 3 Trials
H.C. Wainwright says Novartis success in RMS trials does not impact TG’s Briumvi
After Novartis (NVS) announced topline data from the REMODEL-1/-2 trials of remibrutinib in relapsing multiple sclerosis, H.C. Wainwright analyst Emily Bodnar believes that remibrutinib will be favore...
Novartis Reported Encouraging Trial Data for a Multiple Sclerosis Drug. The Stock Is Jumping
Promising results from a recent clinical trial are boosting Novartis shares this morning.
Novartis Stock (NVS) Pops as Multiple Sclerosis Drug Shows Positive Results in Late-Stage Trials
Novartis ($NVS) stock rose about 6% at the time of writing on Tuesday, after the Swiss drugmaker reported positive results from two late-stage trials of remibrutinib in relapsing multiple sclerosis.
Novartis Halts Eight Trials After Three Patient Deaths
Novartis Halts Eight Trials After Three Patient Deaths
Why Novartis Just Surged 6%, Eyeing A Breakout
Novartis stock surged early Tuesday after its experimental multiple sclerosis treatment succeeded in a pair of midstage studies.
Why Novartis Stock Is Heading for Its Best Day Since 2023 After 3 Patient Deaths
Novartis says it has paused clinical trials for rap-cel in patients with autoimmune disease, while reporting positive data for a different potential blockbuster.
Novartis' Phase 3 REMODEL Trials For Remibrutinib In Multiple Sclerosis Meet Primary Endpoint
(RTTNews) - Novartis AG (NVS), a pharmaceutical company, released on Tuesday positive topline results from the Phase 3 REMODEL-1 and REMODEL-2 trials for remibrutinib in adults with relapsing multiple...
Sandisk, Marvell, Robinhood, Novartis, Dell, and More Stocks That Explain Today's Market
AI stocks including Sandisk, Corning, and Intel struggle as investors ditch risk assets amid a run-up in bond yields.
Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials
Novartis shares rose after the drugmaker reported positive results in two late-stage trials from its new pill for the most common form of multiple sclerosis.
Novartis announces results from Phase III Remodel-1/-2 trials of remibrutinib
Novartis (NVS) announced positive topline results from its Phase III Remodel-1/-2 trials of remibrutinib in relapsing multiple sclerosis. Remibrutinib, a highly selective and potent oral Bruton’s tyro...